Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Status:
Completed
Trial end date:
2020-07-23
Target enrollment:
Participant gender:
Summary
A two-period, two-treatment, crossover study to evaluate the safety, tolerability and
efficacy of amifampridine phosphate in ambulatory patients diagnosed with spinal muscular
atrophy (SMA) Type 3.